David Kirn plans sale of 69,076 4D Molecular shares

4D Molecular Therapeutics, Inc. (FDMT) reports that David Kirn has filed to sell shares of the company’s Class A Common Stock under Rule 144.

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) reports that David Kirn has filed to sell shares of the company’s Class A Common Stock under Rule 144. The notice covers up to 69,076 shares, with an aggregate market value of $1,157,713.76, to be sold through Goldman Sachs & Co. LLC.

The sales are made pursuant to a Rule 10b5-1(c) selling plan dated 01/09/2026. The company discloses that 55,244,211 shares of Class A Common were outstanding. Prior sales by David Kirn in the past three months include, for example, 114,746 shares on 06/22/2026 for $1,200,851.31.

Key Figures

Shares to be sold: 69,076 shares Aggregate market value of shares to be sold: $1,157,713.76 Shares outstanding: 55,244,211 shares +4 more

7 metrics

Shares to be sold 69,076 shares Class A Common Stock covered by the Rule 144 notice

Aggregate market value of shares to be sold $1,157,713.76 Market value of the 69,076 shares in the notice

Shares outstanding 55,244,211 shares Class A Common shares outstanding for 4D Molecular Therapeutics, Inc.

Large prior sale 114,746 shares for $1,200,851.31 Sale by David Kirn on 06/22/2026

Prior sale example 42,608 shares for $548,177.48 Sale by David Kirn on 07/09/2026

Shares from private transaction 19,076 shares Acquired from issuer in private transaction on 12/15/2020

Shares from stock option compensation 50,000 shares Acquired as compensation via stock options on 03/06/2025

Key Terms

Rule 144, Rule 10b5-1(c), cashless exercise, selling plan

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"selling plan dated 01/09/2026 that is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

cashless exercise financial

"Compensation -- Cashless exercise / same-day sale"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

selling plan financial

"made in connection with a selling plan dated 01/09/2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the FDMT Form 144 filing by David Kirn disclose?

The filing discloses that David Kirn plans to sell up to 69,076 FDMT Class A Common shares under Rule 144 through Goldman Sachs & Co. LLC, with an aggregate market value of $1,157,713.76, pursuant to a pre-arranged Rule 10b5-1(c) selling plan.

How many FDMT shares are outstanding according to this Form 144?

The notice states that 55,244,211 shares of 4D Molecular Therapeutics Class A Common were outstanding. This figure provides context for the planned 69,076-share sale, indicating the relative size of the proposed disposition compared with the company’s total shares outstanding.

What is the value of FDMT shares covered by David Kirn’s planned Rule 144 sale?

The planned sale covers shares with an aggregate market value of $1,157,713.76. This amount reflects the market value associated with the 69,076 FDMT Class A Common shares included in the notice, as referenced in the Form 144 securities information section.

What prior FDMT share sales by David Kirn are disclosed in the past three months?

Disclosed past three-month sales include, among others, 114,746 shares on 06/22/2026 for $1,200,851.31 and 42,608 shares on 07/09/2026 for $548,177.48. These transactions are separate from the 69,076 shares covered by the new notice.

How were the FDMT shares to be sold by David Kirn originally acquired?

The notice indicates 19,076 shares were acquired from the issuer in a private transaction on 12/15/2020, and 50,000 shares were acquired as compensation via stock options on 03/06/2025 through a cashless exercise / same-day sale structure.

Is David Kirn’s FDMT share sale under a Rule 10b5-1 trading plan?

Yes. The remarks state the sales are made in connection with a selling plan dated 01/09/2026 that is intended to comply with Rule 10b5-1(c). Such plans pre-establish trading parameters to allow systematic selling over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 06:29 PM Accepted by SEC EDGAR 08/19/2026 - 06:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001834021
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	4D Molecular Therapeutics, Inc.
SEC File Number	001-39782
Address of Issuer	5858 Horton Street Suite 455 Emeryville CALIFORNIA 94608
Phone	1-510-505-2680
Name of Person for Whose Account the Securities are To Be Sold	David Kirn
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	69076	1157713.76	55244211	08/19/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	12/15/2020	Acquired from issuer in private transaction	Issuer			19076	12/15/2020	None
Class A Common	03/06/2025	Acquired as compensation -- Stock Options	Issuer			50000	03/06/2025	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	08/03/2026	12415	124722.33
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	06/01/2026	1922	19257.86
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	06/22/2026	114746	1200851.31
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	07/09/2026	42608	548177.48
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	07/10/2026	15725	189233.08
David Kirn 5858 Horton Street Suite 455 Emeryville CA 94608	Class A Common	08/04/2026	26842	274596.34

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 01/09/2026 that is intended to comply with Rule 10b5-1(c).
Date of Notice	08/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of David Kirn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)